A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutationMarta Castroviejo‐Bermejo, Violeta Serra, Mandy Ducy et al.|EMBO Molecular Medicine|2018Cited by 271
Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with ImmunotherapyElena Garralda, Rodrigo A. Toledo, Charles W. Abbott et al.|Clinical Cancer Research|2025Cited by 1